Cargando…

Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)

PURPOSE: Although the Palliative Prognostic Index (PPI) has been used to predict survival in various cancers, to our knowledge, no study has examined its applicability in gastric cancer. This study aimed to determine the baseline PPI cutoff value for recommending single-fraction radiotherapy in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekii, Shuhei, Saito, Tetsuo, Kosugi, Takashi, Nakamura, Naoki, Wada, Hitoshi, Tonari, Ayako, Ogawa, Hirofumi, Mitsuhashi, Norio, Yamada, Kazunari, Takahashi, Takeo, Ito, Kei, Kawamoto, Terufumi, Araki, Norio, Nozaki, Miwako, Heianna, Joichi, Murotani, Kenta, Hirano, Yasuhiro, Satoh, Atai, Onoe, Tsuyoshi, Shikama, Naoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339127/
https://www.ncbi.nlm.nih.gov/pubmed/37457019
http://dx.doi.org/10.1016/j.ctro.2023.100657
_version_ 1785071783779500032
author Sekii, Shuhei
Saito, Tetsuo
Kosugi, Takashi
Nakamura, Naoki
Wada, Hitoshi
Tonari, Ayako
Ogawa, Hirofumi
Mitsuhashi, Norio
Yamada, Kazunari
Takahashi, Takeo
Ito, Kei
Kawamoto, Terufumi
Araki, Norio
Nozaki, Miwako
Heianna, Joichi
Murotani, Kenta
Hirano, Yasuhiro
Satoh, Atai
Onoe, Tsuyoshi
Shikama, Naoto
author_facet Sekii, Shuhei
Saito, Tetsuo
Kosugi, Takashi
Nakamura, Naoki
Wada, Hitoshi
Tonari, Ayako
Ogawa, Hirofumi
Mitsuhashi, Norio
Yamada, Kazunari
Takahashi, Takeo
Ito, Kei
Kawamoto, Terufumi
Araki, Norio
Nozaki, Miwako
Heianna, Joichi
Murotani, Kenta
Hirano, Yasuhiro
Satoh, Atai
Onoe, Tsuyoshi
Shikama, Naoto
author_sort Sekii, Shuhei
collection PubMed
description PURPOSE: Although the Palliative Prognostic Index (PPI) has been used to predict survival in various cancers, to our knowledge, no study has examined its applicability in gastric cancer. This study aimed to determine the baseline PPI cutoff value for recommending single-fraction radiotherapy in patients with bleeding gastric cancer. MATERIALS AND METHODS: This was a secondary analysis of the Japanese Radiation Oncology Study Group (JROSG) 17–3, a multicenter prospective study of palliative radiotherapy for bleeding gastric cancer. Discrimination was evaluated using a time-dependent receiver operating characteristic curve, and the optimal cutoff value was determined using the Youden index. A calibration plot was used to assess the agreement between predicted and observed survival. RESULTS: We enrolled 55 patients in JROSG 17–3. The respective median survival times were 6.7, 2.8, and 1.0 months (p = 0.021) for patients with baseline PPI scores of ≤ 2, 2 < PPI ≤ 4, and PPI > 4. The areas under the curve for predicting death within 2, 3, 4, and 5 months were 0.813, 0.787, 0.775, and 0.721, respectively. The negative predictive value was highest when survival < 2 months was predicted and the Youden index was highest when the cutoff PPI value was 2. The calibration curve showed a reasonable agreement between the predicted and observed survival. CONCLUSION: Baseline PPI is useful for estimating short-term prognosis in patients treated with palliative radiotherapy for gastric cancer bleeding. A cutoff PPI value of 2 for estimating survival ≤ 2 months should be used to recommend single-fraction radiotherapy.
format Online
Article
Text
id pubmed-10339127
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103391272023-07-14 Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3) Sekii, Shuhei Saito, Tetsuo Kosugi, Takashi Nakamura, Naoki Wada, Hitoshi Tonari, Ayako Ogawa, Hirofumi Mitsuhashi, Norio Yamada, Kazunari Takahashi, Takeo Ito, Kei Kawamoto, Terufumi Araki, Norio Nozaki, Miwako Heianna, Joichi Murotani, Kenta Hirano, Yasuhiro Satoh, Atai Onoe, Tsuyoshi Shikama, Naoto Clin Transl Radiat Oncol Original Research Article PURPOSE: Although the Palliative Prognostic Index (PPI) has been used to predict survival in various cancers, to our knowledge, no study has examined its applicability in gastric cancer. This study aimed to determine the baseline PPI cutoff value for recommending single-fraction radiotherapy in patients with bleeding gastric cancer. MATERIALS AND METHODS: This was a secondary analysis of the Japanese Radiation Oncology Study Group (JROSG) 17–3, a multicenter prospective study of palliative radiotherapy for bleeding gastric cancer. Discrimination was evaluated using a time-dependent receiver operating characteristic curve, and the optimal cutoff value was determined using the Youden index. A calibration plot was used to assess the agreement between predicted and observed survival. RESULTS: We enrolled 55 patients in JROSG 17–3. The respective median survival times were 6.7, 2.8, and 1.0 months (p = 0.021) for patients with baseline PPI scores of ≤ 2, 2 < PPI ≤ 4, and PPI > 4. The areas under the curve for predicting death within 2, 3, 4, and 5 months were 0.813, 0.787, 0.775, and 0.721, respectively. The negative predictive value was highest when survival < 2 months was predicted and the Youden index was highest when the cutoff PPI value was 2. The calibration curve showed a reasonable agreement between the predicted and observed survival. CONCLUSION: Baseline PPI is useful for estimating short-term prognosis in patients treated with palliative radiotherapy for gastric cancer bleeding. A cutoff PPI value of 2 for estimating survival ≤ 2 months should be used to recommend single-fraction radiotherapy. Elsevier 2023-07-03 /pmc/articles/PMC10339127/ /pubmed/37457019 http://dx.doi.org/10.1016/j.ctro.2023.100657 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Research Article
Sekii, Shuhei
Saito, Tetsuo
Kosugi, Takashi
Nakamura, Naoki
Wada, Hitoshi
Tonari, Ayako
Ogawa, Hirofumi
Mitsuhashi, Norio
Yamada, Kazunari
Takahashi, Takeo
Ito, Kei
Kawamoto, Terufumi
Araki, Norio
Nozaki, Miwako
Heianna, Joichi
Murotani, Kenta
Hirano, Yasuhiro
Satoh, Atai
Onoe, Tsuyoshi
Shikama, Naoto
Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title_full Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title_fullStr Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title_full_unstemmed Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title_short Who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: An exploratory analysis of a multicenter prospective observational study (JROSG 17-3)
title_sort who should receive single-fraction palliative radiotherapy for gastric cancer bleeding?: an exploratory analysis of a multicenter prospective observational study (jrosg 17-3)
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339127/
https://www.ncbi.nlm.nih.gov/pubmed/37457019
http://dx.doi.org/10.1016/j.ctro.2023.100657
work_keys_str_mv AT sekiishuhei whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT saitotetsuo whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT kosugitakashi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT nakamuranaoki whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT wadahitoshi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT tonariayako whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT ogawahirofumi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT mitsuhashinorio whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT yamadakazunari whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT takahashitakeo whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT itokei whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT kawamototerufumi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT arakinorio whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT nozakimiwako whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT heiannajoichi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT murotanikenta whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT hiranoyasuhiro whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT satohatai whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT onoetsuyoshi whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173
AT shikamanaoto whoshouldreceivesinglefractionpalliativeradiotherapyforgastriccancerbleedinganexploratoryanalysisofamulticenterprospectiveobservationalstudyjrosg173